Originally published as JCO Early Release 10.1200/JCO.2008.20.0691 on March 16 2009

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanvetyanon, T. Articles by Trotti, A. Search for Related Content PubMed PubMed Citation Articles by Tanvetyanon, T. Articles by Trotti, A. Social Bookmarking                            What's this?

Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer

From the Head and Neck and Thoracic Programs, and the Statistic Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Corresponding author: Tawee Tanvetyanon MD, 12902 Magnolia Dr, Tampa FL 33612; e-mail: tanvett{at}moffitt.org.

Purpose Patients who develop recurrent or new primary head and neck cancer in a previously irradiated site have poor prognosis. Reirradiation is a treatment option, although it is associated with substantial toxicities. We investigated potential prognostic factors, including comorbidity and pre-existing organ dysfunction, for survival after reirradiation.

Methods Institutional electronic records of patients treated with reirradiation between January 1998 and 2008 were reviewed. Comorbidity was assessed by Charlson index and Adult Comorbidity Evaluation-27 (ACE-27) grading. Organ dysfunction was defined as feeding tube dependency, functioning tracheostomy, or soft tissue defect.

Results There were 103 patients, including 46 patients who underwent salvage surgery before reirradiation. Median progression-free and overall survivals were 12.1 months (95% CI, 9.7 to 16.6) and 19.3 months (95% CI, 13.9 to 29.9), respectively. Significant comorbidity was present in 36% of patients by Charlson index and 24% by ACE-27. Baseline organ dysfunction was present in 37% of patients. Median overall survivals were 5.5 months among those with both organ dysfunction and comorbidity per Charlson index, and 4.9 months per ACE-27, compared with 59.6 and 44.2 months, respectively, among the patients with neither organ dysfunction nor comorbidity (P < .001 and < .001). Other independent prognostic factors were interval from previous radiation, recurrent tumor stage, tumor bulk at reirradiation, and reirradiation dose. A nomogram to predict the probability of death within 24 months after reirradiation was developed (concordance index = 0.75).

Conclusion Comorbidity and pre-existing organ dysfunction are among several important prognostic factors for patients undergoing reirradiation. For those with both comorbidity and organ dysfunction, reirradiation largely serves as a palliative therapy.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. A. Iseli, C. E. Iseli, E. L. Rosenthal, J. J. Caudell, S. A. Spencer, J. S. Magnuson, A. N. Smith, and W. R. Carroll Postoperative Reirradiation for Mucosal Head and Neck Squamous Cell Carcinomas Arch Otolaryngol Head Neck Surg, November 1, 2009; 135(11): 1158 - 1164. [Abstract] [Full Text] [PDF]